CDK2-IN-4; full listing in Supplementary Table S4) to find out their mutational standing in tumors of enrolled patients as a potential biomarker of therapeutic response. DNA was extracted from readily available tumor samples (in primary tumors applying neuroblastoma patient genomics details. We utilized an aggregated dataset of 88 diagnostic neurob